par Pepersack, Thierry
Référence Revue médicale de Bruxelles, 36, 4, page (365-372)
Publication Publié, 2015-09
Article révisé par les pairs
Résumé : Atrial fibrillation (AF) increases the risk of mortality and stroke. The prevention of these complications is based on oral anticoagulants that are more efficient than salycilates. As compared with antivitamins K agents, new oral anticoagulants are promising for patients presenting non valvular atrial fibrillation because of lower cerebral hemorragic risk (with respect of assessment of renal function and therapeutic compliance). Available studies and recommendations are presented.

Documents en relation

DI-fusion